Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

Semax: what it is studied alongside

Semax is a synthetic ACTH(4-10) analogue heptapeptide studied in animal and in vitro models of neurodegeneration, ischemia, oxidative stress and neural injury, frequently alongside copper-chelating, antioxidant and gene-

peptides-pro Editorial

Semax is the working name for a synthetic heptapeptide of the ACTH(4-10) analogue class, with the sequence Met-Glu-His-Phe-Pro-Gly-Pro and the alternate designation ACTH(4-7)PGP [2][5]. It is a research peptide, not a therapeutic product, and the identifiers that recur across the literature are its seven-residue sequence and its classification as a synthetic regulatory peptide with high affinity for Cu(II) ions [2]. The catalogue entry for the research-grade material is Semax.

The work around this compound centres on neuroprotective and neuromodulatory signalling, with the adrenocorticotropic hormone (ACTH) peptide family as the reference frame and, in several reports, the μ opioid receptor gene Oprm1 as a downstream target [5][6][8].

Research Studies

Semax and amyloidosis in transgenic Alzheimer's disease models

Semax and a derivative were assessed for effects on behavioural characteristics and the development of amyloidosis in transgenic animals used as an Alzheimer's disease model [1]. The paper frames the work against the absence of remedies that are both effective and sufficiently safe for the disease process, and positions natural peptide drugs as a category of interest on that basis [1]. The findings reported are from the animal model, not from human participants [1].

Semax and Cu(II)-catalysed reactive oxygen species in Aβ systems

In vitro work examined whether Semax can inhibit copper-catalysed oxidation of Aβ [2]. The reported results indicate that the peptide is able to extract Cu(II) from Cu(II)-Aβ species and to influence the redox behaviour of the complex, described as metal ion stripping and redox silencing [2]. The rationale given is that reactive oxygen species generated in a Fenton-like reaction tied to Cu(II)/Cu(I) redox cycling of the Cu(II)-Aβ complex may play a key role in the molecular mechanism of neurotoxicity in Alzheimer's disease [2]. This is an in vitro finding [2].

Semax and gene expression in the penumbra after transient middle cerebral artery occlusion

Two RNA-Seq studies in rats used the transient middle cerebral artery occlusion (tMCAO) model and profiled the penumbra-associated region of the frontal cortex [5][6]. At 24 h after occlusion, Semax and the related peptide ACTH(6-9)PGP were associated with differentially expressed genes, and the peptides significantly reduced the profile disturbances caused by ischemia across a large set of transcripts [5]. An earlier analysis at 4.5 h after tMCAO in the ipsilateral frontal cortex had first revealed differentially expressed genes associated with the same peptides [6]. Both datasets are from rat brain tissue [5][6].

Semax and intracellular calcium dynamics in rat brain neurons

Semax has been studied for effects on spontaneous fluctuations of intracellular calcium ion concentration in pyramidal neurons of hippocampal slices, and on the proton-induced increase in intracellular calcium in cerebellar granule cells of cerebellar slices [7]. The preparation used was 1 μM Semax applied to the slice [7]. This is an ex vivo slice study in rat tissue [7].

Semax and the μ opioid receptor gene Oprm1 after spinal cord injury

In female mice, Semax was reported to target the μ opioid receptor gene Oprm1, promoting deubiquitination and functional recovery after spinal cord injury [8]. The stated background is that lysosomal membrane permeabilization is exacerbated after spinal cord injury and leads to increased neuronal cell death, with ubiquitination affecting that process by regulating the stability and functionality of lysosomal membranes [8]. The observations are from a mouse injury model [8].

Semax and stress-related behaviour in male rats

Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogues Semax and Melanotan II were examined in male rats under a chronic unpredictable stress model [9]. The framing notes that current antidepressant therapy has substantial limitations and that stressful events and hyperactivity of the hypothalamic-pituitary-adrenal axis play an important role in the pathogenesis of depression [9]. The readouts are behavioural and endocrine in rats [9].

Semax and peptide therapeutics in gerontology

A narrative review of therapeutic peptides in gerontology covers mechanisms, clinical applications, evidence base and safety profiles for peptides with demonstrated or potential applications in healthy aging and age-related conditions, targeting hallmarks that include metabolic dysfunction, telomere attrition, tissue repair impairment and hormonal decline [4]. The review draws on PubMed, Scopus and regulatory databases [4]. It is a review, and it does not report a Semax-specific trial [4].

Semax and peptide applications in orthopaedics

A separate review addresses therapeutic peptides in orthopaedics, describing them as adjuncts grounded in modulation of molecular signalling networks, with pathways such as PI3K/Akt, mTOR, MAPK, TGF-β and AMPK named as points of influence over tissue regeneration [10]. This is a review of the broader peptide field rather than a Semax study [10].

Semax and the ACTH-like peptide family in ischemic damage

Across the ischemia work, the recurring comparison is between Semax and the related ACTH(6-9)PGP peptide, both built on the ACTH backbone and both applied in the same rat tMCAO paradigm [5][6]. The table below sets out the two peptides as they appear in those reports.

PeptideDesignation used in the ischemia reportsModelReadout
SemaxACTH(4-7)PGPRat tMCAO, frontal cortexDifferentially expressed genes at 4.5 h and 24 h [5][6]
ACTH(6-9)PGPACTH(6-9)PGPRat tMCAO, frontal cortexDifferentially expressed genes at 4.5 h and 24 h [5][6]

Semax and the copper-binding property as a shared thread

The Cu(II) affinity reported in the in vitro Aβ work is the property most often carried into discussions of the peptide's behaviour in other systems [2]. The same paper describes Semax as a synthetic regulatory peptide and reports both extraction of Cu(II) from Cu(II)-Aβ species and an influence on the redox behaviour of the complex [2]. No human data are presented in that report [2].

What the evidence does and does not cover

The studies above are animal, ex vivo slice, in vitro or review in nature [1][2][4][5][6][7][8][9][10]. Where a finding is described, the population is named: transgenic animals in an Alzheimer's disease model [1], rat frontal cortex after tMCAO [5][6], rat hippocampal and cerebellar slices [7], female mice after spinal cord injury [8], and male rats under chronic unpredictable stress [9]. No human dosing, human efficacy or human safety data appear in the evidence summarised here.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp